Trial Profile
A Phase 1 study of ONO-4538 in combination with chemotherapy in patients with stage IIIB/IV or recurrent NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 01 Jun 2020 Results published in the Cancer Science
- 12 Feb 2018 Planned End Date changed from 1 Mar 2017 to 1 Mar 2020.
- 18 Oct 2017 Results (n=24) assessing long term follow up of tolerability, safety and pharmacokinetics presented at the 18th World Conference on Lung Cancer.